Street Calls of the Week
Investing.com -- Alx Oncology Holdings Inc. (NASDAQ:ALXO) stock surged 10.6% on Thursday after the clinical-stage biotechnology company presented preclinical data for its antibody-drug conjugate (ADC) candidate, ALX2004, at the 2025 AACR-NCI-EORTC International Conference.
The company showcased data demonstrating "potent anti-tumor activity and a favorable toxicity profile" for ALX2004, which targets EGFR-expressing solid tumors. The ADC candidate is designed to overcome toxicity challenges that have limited earlier generation ADCs in this therapeutic area.
ALX2004, developed using the company’s proprietary topoisomerase I inhibitor payload and linker platform, employs a matuzumab-derived EGFR antibody specifically selected to minimize skin toxicity while maximizing therapeutic window. The company noted that the antibody has a binding epitope distinct from FDA-approved EGFR antibodies.
"Given that toxicity challenges of earlier generation ADCs have limited the therapeutic window in the treatment of EGFR-expressing solid tumors; we are encouraged by our preclinical data that this unique molecule, ALX2004 could potentially overcome these limitations," said Jason Lettmann, Chief Executive Officer at ALX Oncology.
The company is currently conducting a Phase 1 clinical trial (NCT07085091) to evaluate ALX2004’s safety, tolerability, and preliminary efficacy in patients with advanced or metastatic solid tumors that express EGFR. Enrollment began in August, with initial safety data expected in the first half of next year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.